EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical

Paulina Apostolova iD, Marija Atanasova Lazareva iD, Katarina Davalieva iD, Marija Arev iD, Dino Karpicarov iD, Petre Makreski iD, Irena Slaveska Spirevska iD, Ivana Mitrevska iD, Aleksandar Dimovski iD, Sanja Vranješ-Đurić iD, Emilija Janevik-Ivanovska iD

Acta Pharmaceutica · 01.06.2026 · 76 (2) · 1-16

DOI: 10.2478/acph-2026-0013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica, online erschienen am 30.06.2026. Verfasst von Paulina Apostolova und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Faculty of Medical Sciences, Goce Delcev University, 2000Stip, North Macedonia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Radiopharmaceuticals, Immunoconjugates. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daratumumab is a fully human anti-CD38 monoclonal antibody with strong potential as a targeting vector for therapeutic radionuclides. This study aimed to develop a freeze-dried daratumumab immunoconjugate kit by selecting a suitable chelator (DOTA-NHS, p -SCN-Bn-DOTA, or p -SCN-Bn-1B4M-DTPA) for the 177 Lu-labelling, optimising the freeze-drying formulation, and evaluating the physicochemical properties and purity profiles. Conjugation performed in carbonate buffer at elevated temperature enhanced chelator incorporation and supported the selection of daratumumab- p -SCN-Bn-DOTA as the most suitable candidate, achieving radiolabelling yield up to 99.8 % without additional purification. Among the evaluated freeze-dried formulations, a saline-based, buffer-free sucrose-mannitol formulation containing polysorbate 20 (S.F5) provided the most favourable characteristics, including minimal residual moisture and the highest monomer purity with non-detectable HMWS species under the applied SE-HPLC conditions. ATR-FTIR and Raman spectroscopy confirmed preservation of the antibody structural integrity after conjugation and freeze-drying. In an in vitro study using human serum, [ 177 Lu]Lu-daratumumab- p -SCNBn-DOTA maintained higher radiochemical purity for 168 h than [ 177 Lu]Lu-daratumumab- p -SCN-Bn-1B4MDTPA, indicating greater stability. These results support the feasibility of a ready-to-use freeze-dried daratumumab- p -SCN-Bn-DOTA kit for the 177 Lu-labelling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalRadiopharmaceuticalsImmunoconjugatesFreeze DryingChemistry, PharmaceuticalLutetiumRadioisotopesDrug CompoundingChelating AgentsHumansHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

177Lu-radio-pharmaceuticaldaratumumabfreeze--dryingimmunoconjugatephysicochemical characterizationready-to-use kit formulation

Substanzen

Antibodies, MonoclonalRadiopharmaceuticalsdaratumumabLutetiumRadioisotopesImmunoconjugatesChelating AgentsLutetium-177Heterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • 1Faculty of Medical Sciences, Goce Delcev University, 2000Stip, North Macedonia.
  • 2University Institute of Positron Emission Tomography, 1000Skopje, North Macedonia.
  • 3Research Centre for Genetic Engineering and Biotechnology "Georgi D Efremov" Macedonian Academy of Sciences and Arts 1000 Skopje, North Macedonia.
  • 4Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, 1000Skopje, North Macedonia.
  • 5Replek Farm Ltd., 1000Skopje, North Macedonia.
  • 7Quality Assurance, ALKALOID AD Skopje, 1000 Skopje, North Macedonia.

ORCID-Profile: Paulina Apostolova, Marija Atanasova Lazareva, Katarina Davalieva, Marija Arev, Dino Karpicarov, Petre Makreski, Irena Slaveska Spirevska, Ivana Mitrevska, Aleksandar Dimovski, Sanja Vranješ-Đurić, Emilija Janevik-Ivanovska

Zitieren

APA

Apostolova, P., Lazareva, M. A., Davalieva, K., Arev, M., Karpicarov, D., Makreski, P., Spirevska, I. S., Mitrevska, I., Dimovski, A., Vranješ-Đurić, S., & Janevik-Ivanovska, E. (2026). Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical. Acta Pharmaceutica, 76(2), 1-16. https://doi.org/10.2478/acph-2026-0013

Vancouver

Apostolova P, Lazareva MA, Davalieva K, Arev M, Karpicarov D, Makreski P, et al. Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical. Acta Pharmaceutica. 2026;76(2):1-16. doi:10.2478/acph-2026-0013

BibTeX
@article{Apostolova2026,
  author = {Apostolova, Paulina and Lazareva, Marija Atanasova and Davalieva, Katarina and Arev, Marija and Karpicarov, Dino and Makreski, Petre and Spirevska, Irena Slaveska and Mitrevska, Ivana and Dimovski, Aleksandar and Vranješ-Đurić, Sanja and Janevik-Ivanovska, Emilija},
  title = {Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical},
  journal = {Acta Pharmaceutica},
  year = {2026},
  volume = {76},
  number = {2},
  pages = {1--16},
  doi = {10.2478/acph-2026-0013}
}
Kostenlos starten →